Dementia treatment combines medications that slow cognitive decline or manage symptoms with non-drug approaches that can meaningfully improve quality of life. There is no cure for most forms of dementia, but the treatment landscape has shifted significantly in recent years, with newer therapies that target the underlying disease process in Alzheimer’s and well-established strategies for managing daily symptoms across all dementia types.
Medications That Slow Cognitive Decline
For decades, dementia drugs could only treat symptoms. That changed with a new class of medications, infusion-based antibody therapies, designed to clear amyloid plaques from the brain. These plaques are a hallmark of Alzheimer’s disease and are believed to drive much of the damage. One of the most recent, donanemab (brand name Kisunla), was approved by the FDA for adults with mild cognitive impairment or mild dementia stage Alzheimer’s. It’s given as an intravenous infusion every four weeks.
In clinical trials, donanemab slowed the rate of cognitive decline by about 35% over 76 weeks in people with lower levels of a protein called tau, which tracks closely with disease severity. In a broader group of patients that included people with more advanced tau buildup, the slowing was about 22%. These are meaningful but modest numbers. The treatment doesn’t stop decline; it slows it. And it only works for people in early stages of Alzheimer’s, not for those with moderate or severe disease.
These newer therapies carry a notable risk: brain swelling or small brain bleeds, collectively known as amyloid-related imaging abnormalities, or ARIA. Across clinical trials of anti-amyloid drugs, roughly 1 in 4 patients showed signs of brain swelling on MRI scans, though only about 7% had symptoms like headache or confusion. People who carry two copies of a specific genetic variant (APOE ε4) face about 5.6 times the odds of developing this side effect compared to non-carriers. Regular MRI monitoring is required during treatment.
Medications That Manage Symptoms
A separate group of drugs doesn’t target the disease itself but helps the brain function better with what it has left. Cholinesterase inhibitors work by boosting levels of a chemical messenger involved in memory and learning. They’re prescribed for mild to moderate Alzheimer’s and some other dementia types, including Lewy body dementia. These drugs can stabilize symptoms for months to a year or more, though they don’t change the long-term trajectory of the disease.
For moderate to severe dementia, a different medication called memantine works by a distinct mechanism. In a healthy brain, a signaling chemical called glutamate helps with learning and memory. But in a damaged brain, excess glutamate activity can become toxic to neurons, accelerating cell death. Memantine blocks this harmful overstimulation while still allowing normal signaling to continue. It’s sometimes prescribed alongside a cholinesterase inhibitor. The combination can help with thinking, daily functioning, and behavior in people with more advanced disease.
Non-Drug Approaches That Work
Non-pharmacological interventions are considered first-line treatment for the behavioral and psychological symptoms of dementia, including agitation, aggression, anxiety, and sleep disturbances. This isn’t a soft recommendation. Clinical consensus places these approaches ahead of medication because they carry fewer risks and, for many symptoms, work just as well or better.
Cognitive stimulation therapy (CST) is one of the most studied. It involves structured group activities, often themed around topics like current events, word games, or creative tasks, designed to actively engage thinking and social interaction. A Cochrane review of 25 studies involving nearly 1,900 participants found that people receiving cognitive stimulation scored about 2 points higher on a standard cognitive test compared to controls. That may sound small, but it represents a clinically meaningful difference, roughly equivalent to the effect of some medications. Participants also reported slight improvements in quality of life.
Music therapy, reminiscence therapy (structured discussions about past experiences using prompts like photos or familiar objects), bright-light therapy for sleep disturbances, and person-centered care approaches all have evidence behind them. The key principle is matching the intervention to the specific symptom. Agitation, for example, often responds well to music or sensory-based approaches, while sleep problems may improve with consistent light exposure during the day and reduced stimulation in the evening.
Managing Vascular Dementia
Vascular dementia, the second most common type, is caused by reduced blood flow to the brain, often from strokes or chronic small-vessel disease. Treatment focuses heavily on controlling cardiovascular risk factors, because preventing further vascular damage is the most effective way to slow progression. The anti-amyloid drugs approved for Alzheimer’s don’t help here.
Blood pressure management is the most important intervention. Research from the American Heart Association has studied targets in the range of 110 to 130 mm Hg systolic for intensive management and 120 to 140 mm Hg for standard care. For older adults without diabetes or kidney disease, targets are typically set at 140/90 or 150/90. Beyond blood pressure, managing cholesterol, blood sugar, and stopping smoking all reduce the risk of further damage. Regular physical activity is particularly important for vascular dementia because it directly improves blood flow to the brain.
Diet and Lifestyle Factors
The MIND diet, a hybrid of the Mediterranean and DASH diets emphasizing leafy greens, berries, nuts, whole grains, fish, and olive oil while limiting red meat, butter, cheese, and fried foods, has been linked to slower cognitive decline in large studies. In a study published in Neurology involving the REGARDS cohort, greater adherence to the MIND diet was associated with lower risk of cognitive impairment and slower rates of decline. The benefits were stronger in women than in men, and Black participants showed a slightly greater protective effect than white participants.
Physical exercise, adequate sleep, social engagement, and management of hearing loss are all modifiable factors with strong evidence for either slowing decline or reducing dementia risk. None of these replace medical treatment, but they form an important layer of any comprehensive plan, especially because they’re accessible and carry essentially no downside.
How Diagnosis Is Changing
Treatment decisions increasingly depend on precise diagnosis, and the tools for that are evolving quickly. New clinical guidelines from the Alzheimer’s Association now support the use of blood-based biomarker tests to help identify Alzheimer’s pathology in people with cognitive symptoms being seen in specialized memory care. These blood tests measure specific proteins, particularly forms of phosphorylated tau, that indicate whether amyloid plaques are present in the brain.
A blood test with 90% or higher sensitivity and at least 75% specificity can be used to rule out Alzheimer’s pathology if the result is negative. A positive result still needs confirmation with a spinal fluid test or brain imaging scan. The guidelines caution that many commercially available blood tests don’t yet meet these accuracy thresholds, and that results should always be interpreted alongside a full clinical evaluation. Still, this represents a significant shift toward earlier and less invasive diagnosis, which matters because the newest treatments only work in the early stages of disease.
What Treatment Looks Like Day to Day
For most people living with dementia, treatment isn’t a single drug or therapy. It’s a combination: possibly a medication to support cognition, structured activities to maintain engagement, environmental adjustments at home to reduce confusion and falls, and ongoing management of other health conditions that can worsen symptoms. Dehydration, urinary tract infections, poor sleep, and unmanaged pain can all cause sudden worsening of confusion that resolves once the underlying issue is addressed.
Caregiver support is also a core part of treatment. Training caregivers in communication strategies, behavioral management techniques, and stress reduction has been shown to reduce behavioral symptoms in the person with dementia and improve outcomes for caregivers themselves. Many dementia care programs now include caregiver education as a standard component rather than an afterthought.